Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma

Matthew Wilson, Barrett G. Haik, Tiebin Liu, Thomas E. Merchant, Carlos Rodriguez-Galindo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

• PURPOSE: To evaluate vincristine and carboplatin with intensive focal treatments in the management of intraocular retinoblastoma. • DESIGN: Noncomparative, retrospective interventional case series. • METHODS: Setting: Institutional. Patient population: Sixteen patients (11 bilateral, 5 unilateral) with intraocular retinoblastoma. Interventional procedures: Patients were treated with eight courses of vincristine and carboplatin. Intensive focal treatments were administered after two courses of chemotherapy. Main outcome measures: Avoidance of external beam radiotherapy (EBRT) and eye survival. • RESULTS: Twenty eyes (74.1%) were classified as Reese-Ellsworth Group V. All eyes responded to chemotherapy. With a median follow-up of 23 months (range 10 to 33 months) and a median of 5.5 focal treatments per eye (range 0 to 19 treatments), ocular survival was 81%. Eight eyes (30%) in five patients received EBRT. • CONCLUSIONS: Vincristine and carboplatin combined with intensive focal treatments is an effective regimen for patients with intraocular retinoblastoma. This treatment regimen has outcomes comparable to those of more toxic regimens and merits further evaluation.

Original languageEnglish (US)
Pages (from-to)397.e1-397.e
JournalAmerican Journal of Ophthalmology
Volume140
Issue number3
DOIs
StatePublished - Jan 1 2005

Fingerprint

Retinoblastoma
Drug Therapy
Carboplatin
Vincristine
Pharmaceutical Preparations
Radiotherapy
Therapeutics
Poisons
Outcome Assessment (Health Care)
Population

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. / Wilson, Matthew; Haik, Barrett G.; Liu, Tiebin; Merchant, Thomas E.; Rodriguez-Galindo, Carlos.

In: American Journal of Ophthalmology, Vol. 140, No. 3, 01.01.2005, p. 397.e1-397.e.

Research output: Contribution to journalArticle

Wilson, Matthew ; Haik, Barrett G. ; Liu, Tiebin ; Merchant, Thomas E. ; Rodriguez-Galindo, Carlos. / Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. In: American Journal of Ophthalmology. 2005 ; Vol. 140, No. 3. pp. 397.e1-397.e.
@article{3ad5c32520974410b834765ef35344c8,
title = "Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma",
abstract = "• PURPOSE: To evaluate vincristine and carboplatin with intensive focal treatments in the management of intraocular retinoblastoma. • DESIGN: Noncomparative, retrospective interventional case series. • METHODS: Setting: Institutional. Patient population: Sixteen patients (11 bilateral, 5 unilateral) with intraocular retinoblastoma. Interventional procedures: Patients were treated with eight courses of vincristine and carboplatin. Intensive focal treatments were administered after two courses of chemotherapy. Main outcome measures: Avoidance of external beam radiotherapy (EBRT) and eye survival. • RESULTS: Twenty eyes (74.1{\%}) were classified as Reese-Ellsworth Group V. All eyes responded to chemotherapy. With a median follow-up of 23 months (range 10 to 33 months) and a median of 5.5 focal treatments per eye (range 0 to 19 treatments), ocular survival was 81{\%}. Eight eyes (30{\%}) in five patients received EBRT. • CONCLUSIONS: Vincristine and carboplatin combined with intensive focal treatments is an effective regimen for patients with intraocular retinoblastoma. This treatment regimen has outcomes comparable to those of more toxic regimens and merits further evaluation.",
author = "Matthew Wilson and Haik, {Barrett G.} and Tiebin Liu and Merchant, {Thomas E.} and Carlos Rodriguez-Galindo",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2005.03.037",
language = "English (US)",
volume = "140",
pages = "397.e1--397.e",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma

AU - Wilson, Matthew

AU - Haik, Barrett G.

AU - Liu, Tiebin

AU - Merchant, Thomas E.

AU - Rodriguez-Galindo, Carlos

PY - 2005/1/1

Y1 - 2005/1/1

N2 - • PURPOSE: To evaluate vincristine and carboplatin with intensive focal treatments in the management of intraocular retinoblastoma. • DESIGN: Noncomparative, retrospective interventional case series. • METHODS: Setting: Institutional. Patient population: Sixteen patients (11 bilateral, 5 unilateral) with intraocular retinoblastoma. Interventional procedures: Patients were treated with eight courses of vincristine and carboplatin. Intensive focal treatments were administered after two courses of chemotherapy. Main outcome measures: Avoidance of external beam radiotherapy (EBRT) and eye survival. • RESULTS: Twenty eyes (74.1%) were classified as Reese-Ellsworth Group V. All eyes responded to chemotherapy. With a median follow-up of 23 months (range 10 to 33 months) and a median of 5.5 focal treatments per eye (range 0 to 19 treatments), ocular survival was 81%. Eight eyes (30%) in five patients received EBRT. • CONCLUSIONS: Vincristine and carboplatin combined with intensive focal treatments is an effective regimen for patients with intraocular retinoblastoma. This treatment regimen has outcomes comparable to those of more toxic regimens and merits further evaluation.

AB - • PURPOSE: To evaluate vincristine and carboplatin with intensive focal treatments in the management of intraocular retinoblastoma. • DESIGN: Noncomparative, retrospective interventional case series. • METHODS: Setting: Institutional. Patient population: Sixteen patients (11 bilateral, 5 unilateral) with intraocular retinoblastoma. Interventional procedures: Patients were treated with eight courses of vincristine and carboplatin. Intensive focal treatments were administered after two courses of chemotherapy. Main outcome measures: Avoidance of external beam radiotherapy (EBRT) and eye survival. • RESULTS: Twenty eyes (74.1%) were classified as Reese-Ellsworth Group V. All eyes responded to chemotherapy. With a median follow-up of 23 months (range 10 to 33 months) and a median of 5.5 focal treatments per eye (range 0 to 19 treatments), ocular survival was 81%. Eight eyes (30%) in five patients received EBRT. • CONCLUSIONS: Vincristine and carboplatin combined with intensive focal treatments is an effective regimen for patients with intraocular retinoblastoma. This treatment regimen has outcomes comparable to those of more toxic regimens and merits further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=24044446891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044446891&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2005.03.037

DO - 10.1016/j.ajo.2005.03.037

M3 - Article

C2 - 16138999

AN - SCOPUS:24044446891

VL - 140

SP - 397.e1-397.e

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -